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Muscarinic receptors modulate 
nerve Growth factor production in 
rat Schwann-like adipose-derived 
stem cells and in Schwann cells
R. piovesana  1,2, A. faroni  2, M. taggi3, A. Matera1, M. Soligo  4, R. canipari3, L. Manni  4, 
A. J. Reid  2,5 ✉ & A. M. tata  1,6 ✉
Regenerative capability of the peripheral nervous system after injury is enhanced by Schwann cells (Scs) 
producing several growth factors. the clinical use of Scs in nerve regeneration strategies is hindered 
by the necessity of removing a healthy nerve to obtain the therapeutic cells. Adipose-derived stem 
cells (ASCs) can be chemically differentiated towards a SC-like phenotype (dASCs), and represent a 
promising alternative to Scs. their physiology can be further modulated pharmacologically by targeting 
receptors for neurotransmitters such as acetylcholine (ACh). In this study, we compare the ability of rat 
dASCs and native SCs to produce NGF in vitro. We also evaluate the ability of muscarinic receptors, in 
particular the M2 subtype, to modulate NGF production and maturation from the precursor (proNGF) to 
the mature (mNGF) form. For the first time, we demonstrate that dASCs produce higher basal levels of 
proNGF and mature NGF compared to SCs. Moreover, muscarinic receptor activation, and in particular 
M2 subtype stimulation, modulates NGF production and maturation in both SCs and dASCs. Indeed, 
both cell types express both proNGF A and B isoforms, as well as mNGF. After M2 receptor stimulation, 
proNGF-B (25 kDa), which is involved in apoptotic processes, is strongly reduced at transcript and 
protein level. Thus, we demonstrate that dASCs possess a stronger neurotrophic potential compared 
to SCs. ACh, via M2 muscarinic receptors, contributes to the modulation and maturation of NGF, 
improving the regenerative properties of dASCs.
Neurotrophins are a group of proteins that specifically stimulate neuronal activity during development, adult life 
and injury, supporting neuron survival, neurite outgrowth and controlling neuron and glial cell differentiation1.
Nerve growth factor (NGF) has particular relevance for the survival and functional activity of sensory and 
sympathetic neurons2,3. NGF is synthesised as a precursor (proNGF) which is proteolytically cleaved to produce 
mature NGF (mNGF)3,4. In particular, two different isoforms of proNGF are described: proNGF-A (32 kDa) and 
proNGF-B (25 kDa)5. There are consistent clues that proNGF-A isoform may act as a modulator of cell survival6, 
whereas proNGF-B isoform acts as an apoptotic signal7. proNGF undergoes post-translational intracellular and 
extracellular processing at both amino- and carboxyl-terminal ends, thanks to the action of plasmin cleavage, 
to produce the mNGF form of 13.2kDa4. Both proNGF and mNGF can be secreted and have active functional 
roles5,7,8. In healthy peripheral nerves, NGF is produced by the target organs and retrogradely transported to the 
neuronal soma1 binding two distinct receptors: the high-affinity Tropomyosin receptor kinase A (TrkA) and the 
low-affinity p75NTR9,10. After nerve injury, axons are dissociated from the source of neurotrophic support, and 
the Schwann cells (SCs) lose their contact with the axons before acquiring the repair phenotype. At this stage, 
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nerve regeneration is promoted by removal of myelin debris and by production of neurotrophic factors including 
NGF, by repair SCs11–13.
Despite the presence of repair SCs, conferring intrinsic regenerative potential to the injured peripheral nerv-
ous system (PNS), full functional recovery is always incomplete. This has driven experimental work on the use of 
cellular therapy as a potential clinical intervention to promote the recovery of injured peripheral nerve; however, 
SCs therapeutic potential is limited by the need to sacrifice a healthy nerve and by their slow in vitro proliferative 
rate14.
Other cell types, such as adipose-derived stem cells (ASCs), possess the ability to differentiate towards SCs 
phenotype (SC-like, dASCs) when exposed to specific growth factors (glial growth factor, GGF; Platelet-Derived 
Growth Factor, PDGF; Basic Fibroblast Growth Factor, bFGF; Forskolin, Fsk)15,16. The ease of ASCs harvesting 
and the rapid differentiation in SCs phenotype make Schwann–like (dASCs) an excellent candidate to further 
investigate for their translational potential in peripheral nerve injury.
In recent years, promising roles have emerged for neurotransmitters17–20, including ACh21–25, in regulating 
important processes in glial cells of the central (CNS) and PNS. Indeed, in the PNS muscarinic receptors are 
present on both neurons and non-neuronal cells of the sensory ganglia26. Furthermore, in the CNS, muscarinic 
receptors are developmentally regulated in oligodendrocytes27. This evidence suggests an important role for ACh 
as mediator of neuron-glia cross-talk in both CNS and PNS28. Rat SCs express distinct muscarinic receptor sub-
types, with greater expression of M2 subtype21. M2 selective activation with agonist Arecaidine Propargyl Ester 
(APE) inhibits SCs proliferation22, upregulating promyelinating genes (e.g. Sox10 and EGR2) and myelin proteins 
(e.g. P0 and MBP)23. dASCs express functional receptors for several neurotransmitters such as GABA, ATP29–31 
and all muscarinic receptor subtypes32,33. In dASCs, M2 receptor activation produces a reversible decrease of 
cell proliferation, reduces migration and enhances dASCs differentiation as shown by improved spindle shaped 
morphology accompanied by early growth factor 2 (EGR2) upregulation33. dASCs produce neurotrophic factors, 
such as BDNF (Brain-derived neurotrophic factor, BDNF) and NGF, which are important for their neurotrophic 
effects as demonstrated in animal models of peripheral nerve regeneration34,35.
In this work, we have evaluated the ability of muscarinic receptors to modulate NGF production and release 
in rat dASCs and SCs. For the first time, we demonstrate that dASCs produce and release higher levels of proNGF 
and mNGF than SCs. We have also analysed the effects of non-selective muscarinic agonist stimulation (muscar-
ine) and M2 selective agonist stimulation (APE) on NGF production and maturation in both dASCs and native 
SCs. Our results indicate that muscarinic receptor activation triggers NGF production both in SCs and in dASCs. 
These results may contribute to define a new pharmacological target, improving the neurotrophic potential of 
dASCs towards new therapeutic approaches for peripheral nerve regeneration.
Results
cholinergic modulation of nGf expression. Firstly, we investigated the ability of muscarinic agonists 
to modulate NGF expression after 24 h of treatment. NGF transcript levels were significantly decreased following 
APE treatments in both dASCs and SCs (Fig. 1A,D), compared to untreated controls, whereas muscarine was able 
to reduce NGF gene expression only in SCs (Fig. 1D).
Gene expression analysis showed that APE exposure was able to upregulate proNGF-A in dASCs compared 
to untreated controls (Fig. 1B), while a significant decrease was observed in SCs (Fig. 1E). On the other hand, the 
non-selective agonist muscarine upregulated proNGF-A transcript only in dASCs (Fig. 1B), but its protein levels 
remained still unmodified (Fig. 1G).
proNGF-B isoform expression was significantly downregulated after APE treatment (Fig. 1C, F), whereas 
muscarine treatment was able to significantly decrease its expression only in dASCs (Fig. 1C).
Following 48 h of exposure to 100 μM of APE or muscarine, rat dASCs did not display any variation of 
proNGF-A protein but showed lower levels of 25 kDa proNGF-B, compared to the untreated cells (Fig. 1G,H).
In SCs, the protein levels of proNGF-A remained unmodified whereas the 25 kDa proNGF-B isoform was 
significantly downregulated following both treatments (Fig. 1I, L).
ProNGF isoforms typically bind low-affinity nerve growth factor receptor p75NTR7,36. qPCR analyses demon-
strated that p75NTR was significantly decreased in dASCs after both muscarinic agonists treatments (Fig. 2A), 
but it was upregulated after muscarine treatment in SCs (Fig. 2B). Immunocytochemistry analysis confirmed 
the expression of p75NTR receptor in both cell types (Fig. 2C), however the expression of the receptor was not 
altered after muscarinic agonists treatments in SCs cells (Fig. 2C). In dASCs, the expression of p75NTR receptor 
was increased upon APE and muscarine treatment (Fig. 2C). Densitometric analysis of p75NTR immunostaining 
demonstrated an increased of p75NTR expression in dASCs upon both muscarinic agonist treatments in dASCs 
(Fig. 2D). Conversely, p75NTR expression was unaltered in SCs upon muscarinic challenge (Fig. 2C, D).
dASCs produce and release higher basal levels of NGF. Several studies described how dASCs produce 
neurotrophic factors increasing the regenerative properties of these cells30,37.
Comparing dASCs with native SCs, we showed that higher levels of proNGF were detectable, by ELISA, after 
24 and 48 h of cultures in both dASCs lysates and in the supernatants (Fig. 3A,C). The baseline concentration 
of proNGF was 2059 ± 256.8 pg/mg in dASCs lysates, whereas in SCs we observed a mean of production of 
473.7 ± 68.69 pg/mg after 24 h of culture, four times lower than dASCs (Fig. 3A, 24 h). After 48 h dASCs produced 
six times more than SCs, with an average of 2124 ± 239.2 pg/mg in dASCs compared to 337.4 ± 45 pg/mg in SCs 
(Fig. 3A, 48h). dASCs released more proNGF in the culture media with a concentration of 736 ± 99.76 pg/mg 
vs 308 ± 78.59 pg/mg in SCs in the first 24 h after plating (Fig. 3C, 24h). After 48h, proNGF concentration was 
897 ± 104.9 pg/mg in dASCs media, five times more than SCs, where it was 176.4 ± 87.68 pg/mg (Fig. 3C, 48h).
In the lysates, mNGF concentrations were lower in dASCs at both time points analysed (Fig. 3B).
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Figure 1. Expression of Nerve Growth Factor in dASCs and SCs after 24 h of cholinergic treatments. (A, D) 
NGF gene expression levels were significantly decreased after 24 h of APE treatment both in dASCs (fold 
change: 0.7213 ± 0.045, ****P < 0.0001; n = 4) and SCs (fold change: 0.5425 ± 0.097, ****P < 0.0001; n = 4), 
whereas muscarine is able to decrease the NGF levels only in SCs (fold change: 0.7395 ± 0.11, *P < 0.05; n = 4). 
After APE and muscarine exposures a proNGF-A consistent upregulation was observed in dASCs (B, APE fold 
change: 3.270 ± 0.82, **P = 0.0048; muscarine fold change: 1.583 ± 0.21; *P < 0.05; n = 4) while a significant 
decrease of proNGF-A was observed in SCs after APE treatment (E, fold change: 0.7239 ± 0.072, **P  = 0.0012; 
n = 4). APE treatment downregulated proNGF-B isoform in both cell types (C, fold change: 0.4724 ± 0.12, 
***P = 0.0007; F, fold change: 0.6589 ± 0.050, ****P < 0.0001; n = 4). A significant downregulation was 
observed in dASCs after muscarine treatment (C, fold change: 0.5168 ± 0.065, ****P < 0.0001; n = 4) whereas 
any effect was observed in SCs (F). (G, I) Western blotting showing expression of different proNGF isoforms. 
After APE exposure, proNGF-B protein levels strongly decreased in both cell types (H, L) (34.78 ± 6.32% vs 
Ctrl, *P < 0.05; 57.05 ± 10.87% vs Ctrl, *P < 0.05; n = 3). After muscarine treatment there was a decrease of 
proNGF-B protein expression but it was significant only in SCs (L, 28.94 ± 9.72% vs Ctrl, **P = 0.0045; n = 3). 
For quantification of western blot analysis, levels of NGF expression were normalised for the housekeeping 
protein β-actin, used as a loading control, and expressed as percentage vs non-treated controls ± SEM.
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The average of concentration after 24 h was 23.43 ± 0.32 pg/mg for dASCs and an average production of 
94.95 ± 19.54 pg/mg in SCs, a four-fold difference. Forty-eight hours after plating, mNGF concentration was 
14.27 ± 1.7 pg/mg in dASCs whereas it was 129.2 ± 13.83 pg/mg in SCs, 9 times more than dASCs (Fig. 3B).
Finally, mNGF concentration was also more elevated in dASCs media than SCs (Fig. 3D). The concentration 
of mNGF was approximately 5 time higher in dASCs than SCs after 24 h (Fig. 3D, dASCs pg/mg=294.4 ± 49.06, 
SCs pg/mg=53.05 ± 14.44), while, after 48 h, mNGF was approximately 9 times higher in dASCs (dASCs pg/
mg=299 ± 31.83, SCs pg/mg=32.2 ± 14.67).
The results obtained suggest that proNGF production and release (Fig. 3A and C), as well as NGF maturation 
(Fig. 3D) seem more efficient in dASCs than in SCs.
cholinergic modulation of pronGf and mnGf production. By ELISA assays, we evaluated 
the amount of proNGF and mNGF production in dASCs (Fig. 4) and SCs (Fig. 5) upon cholinergic agonists 
stimulation.
No significant variations in proNGF levels were observed in dASCs lysates, except for a decrease induced by 
muscarine after 48 h of treatment (Fig. 4A). As demonstrated in Fig. 4B, selective and non-selective cholinergic 
treatments did not influence NGF maturation in the first 24 h of treatment, but a significant upregulation of 
mNGF concentration in cell lysates was observed after 48 h of APE exposure. In dASCs, cholinergic treatments 
did not alter the concentration of proNGF released in the culture media (Fig. 4C). In the cell media, mNGF 
Figure 2. p75NTR expression in dASCs and SCs. Low-affinity nerve growth factor receptor (p75NTR) 
gene expression levels were significantly decreased in dASCs after both drugs exposure (A; APE fold 
change: 0.6896 ± 0.126, *P = 0.0197; muscarine fold change: 0.7443 ± 0.108, **P = 0.0085; n = 4). p75NTR 
was upregulated after muscarine treatment in SCs (B, fold change: 1.250 ± 0.12, *P < 0.05; n = 4). (C) 
Immunocytochemistry analysis of p75NTR protein in dASCs and SCs (scale bar = 200 μm). (D) Analysis 
of fluorescence intensity of p75NTR immunostaining. APE and muscarine treatments increased p75NTR 
expression in dASCs (APE: 261.3 ± 47.07% vs Ctrl, ***P < 0.001; muscarine: 192.3 ± 12.84% vs Ctrl, *P < 0.05).
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concentrations were not affected by muscarinic agonists in the first 24 h of stimulation, while a significant upreg-
ulation after 48 h of muscarine exposure was observed (Fig. 4D).
Using an approach similar to that followed for dASCs, NGF production, maturation and release were eval-
uated in native SCs (Fig. 5). proNGF basal (controls) level production significantly decreased after 48 h of cell 
culture (Fig. 5A). After 24 h of APE treatment, proNGF concentration was significantly increased in cell lysates 
(Fig. 5A), but it was decreased at control levels after 48 h (Fig. 5A). Similarly, muscarine increased proNGF con-
centration in lysates after 24 h of treatment, while a significant decrease was observed after 48 h (Fig. 5A). In SCs 
lysates, NGF maturation was unaltered after 24 h and 48h of exposure to APE and muscarine (Fig. 5B).
Similarly to what observed in cell lysates, in the culture media we observed a significant decrease of the basal 
proNGF released between 24 and 48 h of culture (Fig. 5C). Twenty-four hour of APE exposure increased proNGF 
release (Fig. 5C), while a significant decreased in concentration was observed following 48 h (Fig. 5C). There 
was no significant modulation of proNGF concentration in the cell media after non-selective challenge with 
muscarine.
Basal mNGF released in the cell media was not affected by both selective and non-selective muscarinic chal-
lenge after 24h of treatment, whereas a significant reduction was observed after 48 h in the culture media of cells 
treated with both muscarinic agonists (Fig. 5D).
Figure 3. Basal levels of NGF in dASCs and in SCs. In dASCs lysates higher levels of proNGF were detected 
upon 24 h and 48 h of cultures than in SCs lysates (A, 24 h dASCs pg/mg = 2059 ± 256.8, 24 h SCs pg/mg = 
473.7 ± 68.69, ***P = 0.0001; 48 h dASCs pg/mg=2124 ± 239.2, 48 h SCs pg/mg=337.4 ± 45, ***P = 0.0009; 
n = 3) whereas mNGF is lower than in SCs (B, 24 h dASCs pg/mg=23.43 ± 0.32, 24 h SCs pg/mg=94.95 ± 19.54, 
*P < 0.05, 48 h dASCs pg/mg=14.27 ± 1.7, 48 h SCs pg/mg=129.2 ± 13.83, **P = 0.0025; n = 3). However, 
dASCs release more proNGF (C, 24 h dASCs pg/mg=736 ± 99.76, 24 h SCs pg/mg=308 ± 78.59, *P < 0.05; 48 h 
dASCs pg/mg=897 ± 104.9, 48 h SCs pg/mg=176.4 ± 87.68, ***P = 0.0008; n = 3) and mNGF in the media 
than SCs (D, 24 h dASCs pg/mg=294.4 ± 49.06, 24 h SCs pg/mg=53.05 ± 14.44, ***P = 0.0001; 48 h dASCs pg/
mg=299 ± 31.83, 48 h SCs pg/mg=32.2 ± 14.67, ****P < 0.0001; n = 3).
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Cholinergic modulation of tPA and MMPs activity. Tissue PA enzyme is able to promote the conver-
sion of proNGF into mNGF4. In dASCs, tPA gene expression was increased after cholinergic treatments (Fig. 6A) 
whereas this was not observed in SCs (Fig. 6D). However, tPA activity, measured by zymography, was significantly 
increased in both dASCs and SCs after APE or muscarine exposure (Fig. 6).
Metalloproteinases, in particular MMP9, are responsible of mNGF degradation4 whereas MMP2 plays a rel-
evant role in extracellular matrix remodelling, one of the event necessary to support nerve regeneration and in 
the modulation of pro-inflammatory cytokines (i.e. TNFα)38. As shown in Fig. 7A, MMP9 activity was higher 
in dASCs compared to SCs, whereas MMP2 activity was higher in SCs. MMP2 gene expression was significantly 
upregulated after APE and muscarine treatment in dASCs (Fig. 7C), but not in SCs (Fig. 7E). Conversely, MMP9 
gene expression did not show significative differences in terms of transcript levels in all experimental conditions 
and in neither cell types (data not shown). However, MMP2 and 9 activity, measured by zymography, was not 
influenced by cholinergic treatments, remaining similar to untreated cells (Fig. 7B,D).
Figure 4. ProNGF and mNGF levels in dASCs after muscarinic receptors stimulation. (A) After 24 h of APE 
and muscarine treatment there was a faint increase of proNGF in dASCs lysates (APE: 131.9 ± 14.99% vs 
Ctrl, muscarine: 131.7 ± 17.61% vs Ctrl; n = 3). After 48 h there was a decrease of proNGF production (APE: 
65.01 ± 9.69% vs Ctrl, muscarine: 56.57 ± 6.197% vs Ctrl, **P = 0.0091; n = 3). (B) Cholinergic treatments did 
not influence NGF maturation in the first 24 h of treatment but a strong upregulation of mNGF concentration 
was observed after 48 h of APE exposure (363.6 ± 11.96% vs Ctrl, ****P < 0.0001; n = 3). (C) Cholinergic 
treatments did not significantly modulate proNGF release in the cell media. (D) mNGF concentrations were 
not significantly affected by M2 selective agonist APE (24 h: 55.81 ± 7.86% vs Ctrl, 48 h:137.3 ± 13.31% vs Ctrl; 
n = 3) but a significant upregulation after 48 h of muscarine exposure was observed (242.5 ± 54.51% vs Ctrl, 
**P = 0.0023; n = 3). NGF production was normalised against the mean of control group and expressed as 
percentage vs. untreated controls ± SEM.
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Discussion
A relationship between ACh and NGF in the CNS has been previously reported. Indeed, NGF is important to 
regulate septo-hippocampal physiology and there are potential therapeutic uses in neurodegenerative disorders 
involving a cholinergic deficit39. Moreover, NGF was reported to attenuate cholinergic deficits in a rat model of 
traumatic brain injury40, and NGF gene transfer into aged animals can improve neuronal depolarization induced 
by ACh release from hippocampal synaptic terminals41. Conversely, ACh can regulate neurotrophin metabolism; 
indeed, the cholinergic system is implicated in the modulation of hippocampal NGF and BDNF mRNA expres-
sion, i.e. the injection of muscarinic agonist, pilocarpine, increases hippocampal BDNF and NGF mRNAs in 
postnatal and adult rats42.
Figure 5. ProNGF and mNGF levels in SCs after muscarinic receptors stimulation. (A) proNGF basal level 
production significantly decreased after 48 h of culture (51.28 ± 3.45% vs Ctrl, *P < 0.05; n = 5). In SCs 
lysates, proNGF production increased upon 24 h of APE treatment, (147.4 ± 15.02% vs Ctrl, **P = 0.0045; 
n = 5) followed by decreased levels after 48 h (55.23 ± 4.96% vs Ctrl, ****P < 0.0001; n = 5). Muscarine 
significantly increased proNGF concentration in lysates after 24 h (139.8 ± 17.54% vs Ctrl *P < 0.05; n = 5) 
and decreased its effects after 48 h (54.05 ± 9.88% vs Ctrl, ***P = 0.0002; n = 5). (B) mNGF levels results 
unchanged after 24 h and 48 h of APE and muscarine exposure (24h APE:133.3 ± 16.62% vs Ctrl, 48h APE: 
117±20.98% vs Ctrl, 24h muscarine: 169.4 ± 34% vs Ctrl, 48h muscarine: 102.5 ± 13.55% vs Ctrl; n = 5). (C) 
In the media there was a decrease of basal proNGF release (42.02 ± 10.64% vs Ctrl, *P < 0.05; n = 5) whereas 
after APE treatment there was a decrease after 48 h (51.34 ± 11.5% vs Ctrl, ***P = 0.0007; n = 5). Muscarine 
treatment did not exert any significant modulation on proNGF concentration in the media at both time 
points (24 h: 80.15 ± 5.94% vs Ctrl; 48h: 40.35 ± 9.99% vs Ctrl; n = 5). proNGF release was reduced after 48h. 
(D) APE and muscarine significantly decreased mNGF after 48 h of exposure (APE: 64.82 ±  9.6% vs Ctrl, 
**P = 0.0039; muscarine: 54.68 ± 10.32% vs Ctrl, **P = 0.0080; n = 5). NGF production was normalised against 
the mean of controls and expressed as percentage vs untreated controls ± SEM.
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In the present work we demonstrate for the first time that the pharmacological modulation of muscarinic 
receptors regulates the production and secretion of NGF also in peripheral nervous system, and in particular 
in SCs. Moreover, we also demonstrate the ability of dASCs to produce higher levels of NGF compared to SCs, 
supporting the ability of dASCs in promoting peripheral nerve regeneration.
This work follows our previous study, focused on the effects mediated by M2 muscarinic receptors in rat 
SC-like adipose-derived stem cells33; however, herein we have also analysed the effects of all other muscarinic 
receptors in the modulation of NGF production and release, highlighting the following points:
cholinergic regulation of pro-nGf isoforms. M2 selective activation with APE treatment results in a 
significant decrease of proNGF-B gene and protein expression in both dASCs and SCs; whilst proNGF-A gene 
expression is significantly downregulated in SCs and it is significantly upregulated in dASCs after both APE 
and muscarine treatments. Distinct proNGF isoforms are expressed in mouse tissues, resulting from alterna-
tive splicing and/or activation of different promoters5,43,44; as recently reported, proNGF-A has a pro-survival 
and differentiative effects in vitro6, whereas proNGF-B isoform acts as an apoptotic signal7. The longer variant 
proNGF-A (32–34 kDa) and the shorter variant proNGF-B (25–27 kDa) are produced in both CNS and PNS43–46. 
Our results suggest that muscarinic challenge promotes a proNGF-mediated neuroreparative response in dASCs, 
whilst cholinergic stimulation could improve neuronal survival and axon regeneration via proNGF-A/proNGF-B 
ratio modulation in glial cells.
Effects on the expression of the low affinity p75 receptor. ProNGF preferentially binds the 
low-affinity p75 neurotrophic receptor (P75NTR)47. After APE exposure, p75NTR gene expression decreases in 
dASCs but remains unchanged in SCs; whilst muscarine stimulation decreases p75NTR transcript levels in dASCs 
but promotes its expression in SCs. Interestingly immunocytochemistry analysis demonstrates an increased 
expression of p75NTR protein upon both muscarinic agonists treatment but only in dASCs. Considering recent 
evidence suggesting that several miRNA are involved in the regulation of p75NTR in different physiological and 
pathological conditions48,49, the differential expressions of gene and protein in SCs following APE and muscar-
ine stimulation may indicate p75NTR post-transcriptional regulation. These data, together with the reported 
p75NTR-mediated pro-survival effect of proNGF-A6, support the idea that dASCs could positively promote the 
neuro-reparative process after M2 receptor challenge.
dASCs produce and release higher levels of pro- and mNGF compared to SCs. The comparison 
between proNGF and mNGF content in dASCs and SCs point at the former cell type as a suitable and per-
haps preferable regenerative tool in the treatment of peripheral nerve lesions. To investigate proNGF release and 
Figure 6. Cholinergic modulation of tPA activity. (A) qPCR showed an increased tPA gene expression after 
APE treatment in dASCs (A, fold change: 1.342 ± 0.13, *P < 0.05, n = 3). (D) tPA gene expression was not 
influenced by cholinergic treatments in SCs. tPA activity was significantly upregulated after APE or muscarine 
exposure in dASCs (B, C; APE: 170.9 ± 21.66% vs Ctrl, **P = 0.0028; muscarine: 155.2 ± 7.22% vs Ctrl, 
*P < 0.05; n = 3) and in SCs cells (E, F; APE: 154.1 ± 9.08% vs Ctrl, **P = 0.0025; muscarine: 161.9 ± 10.39% vs 
Ctrl, ***P = 0.0007; n = 3).
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maturation, ELISA was employed with two different antibodies to discriminate proNGF and mNGF50. Our data 
clearly indicate that dASCs produce and release higher levels of proNGF and mNGF than SCs in basal condition. 
In light of previous reports, demonstrating the role of NGF in the process of peripheral nerve regeneration1,11–13, 
our findings suggest that dASCs could supply a larger amount of the neurotrophic factor, if used instead of native 
SCs as nerve-repair promoting tool. It is worth noticing that higher levels of mNGF in dASCs may be produced 
both after proNGF release and proteolytic cleavage in extracellular space and after proNGF intracellular pro-
cessing by furin4.Though this matter deserves more specific investigation, our data suggest that the extracellular 
conversion of proNGF into mNGF is prevalent in the dASCs phenotype.
Figure 7. Metalloproteinases MMP2 and 9 activity in dASCs and in SCs. (A) MMP9 activity, responsible for 
NGF degradation, was significantly more active in dASCs than SCs. MMP2 and 9 activity was not influenced 
by cholinergic treatments in dASCs (B) and SCs (D). (C) MMP2 gene expression was significantly upregulated 
after APE and muscarine treatments in dASCs (APE fold change: 1.194 ± 0.07, *P < 0.05; muscarine fold 
change: 1.691 ± 0.033, ****P < 0.0001; n = 3), (E) whereas MMP2 gene expression was not influenced by 
cholinergic treatments in SCs.
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Cholinergic stimulation differently modulates NGF production in dASCs and SCs. All mus-
carinic receptor activation by muscarine should generate a balance on their effect on NGF metabolism, however it 
is evident that muscarine and APE treatments show similar effects, suggesting that M2 receptor may be the main 
subtype involved in NGF metabolism both in dASCs and SCs. The difference between the two different ligands 
was especially observed in mNGF levels that is higher in dASCs lysates after 48 h of APE exposure and upon 48 h 
of muscarine treatment in cell media. ELISA data also show a relative decrease of proNGF and mNGF concen-
tration after 48 h of treatment, more evident in SCs. These results suggest that in SCs, despite having lower NGF 
levels than dASCs, muscarinic stimulation may contribute to trigger proNGF/mNGF production more efficiently. 
On the other hand, the higher basal levels of proNGF and mNGF observed in dASCs could explain the delayed 
response to muscarinic stimulation in this cell type. This hypothesis is supported by the evidence that in dASCs 
a decrease in proNGF followed by an increase in mNGF cellular content is observed 48 h after APE stimulation, 
indicating that, in these cells, the M2 stimulation promotes proNGF maturation. Conversely, the intracellular 
proNGF increases upon only 24 h of cholinergic treatment in SCs, suggesting that proNGF and mNGF may be 
previously accumulated and then released after cholinergic stimulation in SCs. Overall, these data indicate that 
SCs may be less reactive than dASCs in generating an NGF-based neuro-reparative process in response to mus-
carinic activation.
NGF maturation and degradation machinery is differently expressed and modulated in dASCs 
and Scs. ProNGF can be converted to mNGF in the extracellular environment and the tissue plasminogen 
activator (tPA) is involved in the proNGF to mNGF cleavage4. The tissue plasminogen activator tPA is a key 
enzyme involved in several biological processes, including vascular and tissue remodelling, tumour progres-
sion51 and nervous system pathophysiology52,53. Tissue PA is a secreted protease that converts plasminogen into 
the active protease plasmin, which in turn participates in the cleavage of proNGF into mNGF4. In the PNS, tPA 
activity is elevated during axonal outgrowth and tPA is secreted by primary neurons and cultured SCs54,55, and 
its activity is particularly concentrated in growth cones54. Interestingly, the tPA system is potently induced also 
after peripheral nerve injury in mice56,57. As described above, peripheral nerve regeneration acts on the capacity 
of axons to regrow in a very intricate environment, composed by altered ECM, myelin and axon debris and infil-
trating inflammatory cells. In these hostile conditions axonal growth seems hampered, thus regenerating neurites 
secrete tPA to degrade cell-cell and cell-matrix adhesion molecules. Accordingly, tPA mRNAs are strongly and 
early upregulated after peripheral nerve injury in Schwann cells and neurons, and their activity increases at the 
injury site up to 7 days post-crush58.
We found that tPA gene expression and activity are upregulated after 24 h of muscarinic stimulation both in 
dASCs and SCs. The increase of tPA activity is significant in both dASCs and SCs and this may indicate that the 
cholinergic stimulation may efficiently promote the proNGF maturation. In SCs, the increase of tPA activity is 
less evident, supporting the previous hypothesis that cholinergic stimulation in these cells promotes the proNGF 
and mNGF previously accumulated in the cells. In addition, tPA can convert plasminogen to plasmin, and plas-
min, in turn, can work indirectly through the activation of matrix metalloproteinases (MMPs) to complement its 
degrading activities59. Accordingly, MMP9 is mainly involved in mNGF degradation4.
Although our data demonstrate that APE or muscarine treatments do not regulate the MMPs activity, we 
found a higher activity of MMP9 in dASCs than SCs. This suggests that the increased pro- and mNGF levels in 
dASCs supernatants indicate the possible NGF maturation and degradation in extracellular space by tPA and 
MMP9 activity respectively. MMP2 gene expression is significantly upregulated by cholinergic stimulation in 
dASCs but activity levels remain unchanged. Considering the role of MMP2 in the extracellular matrix remodel-
ling and in the modulation of pro-inflammatory cytokines (i.e. TNFα)38, the presence of MMP2 activity in dASCs 
and in SCs may contribute to the regenerative property of these cells.
conclusions
Our data demonstrate that muscarinic receptors promote the NGF production and maturation in SCs and dASCs. 
The higher levels of basal NGF and the increase of proNGF and mNGF production upon cholinergic stimulation, 
accompanied by an efficient increase of tPA activity and higher levels of MMP9, suggest that dASCs are efficiently 
capable to produce NGF and that this production can be modulated by cholinergic stimulation. In the perspective 
of regenerative medicine, this feature is fundamental, suggesting the use of these cells as a reservoir of neuro-
trophic factors to accelerate the regenerative process. Moreover, it is known that NGF, acting through neuronal 
TrkA, strongly regulates myelination of DRG axons by both SCs and oligodendrocytes60. In accordance with our 
previous work on SCs23 and dASCs33, NGF release could act in an autocrine way, via trkA and p75NTR receptors, 
improving SCs activity during nerve regeneration. This article postulates the first evidence of the involvement 
of muscarinic receptors, and in particular M2 receptor, in the regulation of nerve growth factor expression and 
release in the PNS. Although further analyses are needed to fully elucidate the role of ACh in modulating periph-
eral nerve regeneration, cholinergic receptor stimulation may represent, together with dASCs, a promising and 
clinically applicable pharmacological intervention.
Methods
Statements for experiments involving the use of animals. All the experiments requiring animals 
were performed within the Biological Services Facilities (BSF) at the University of Manchester, in accordance 
with the UK Animals (Scientific Procedures) Act, 1986. Following terminal anaesthesia with CO2 and cervical 
dislocation (Schedule 1), tissues were harvested from the animals and processed as required to obtain the differ-
ent cell cultures.
For experiments performed in Italy, the protocol (7FF2C.6.EXT. 96) has been approved by the Ministry of 
Health (Aut. N. 1184/2016-PR 16/12/2016).
1 1Scientific RepoRtS |         (2020) 10:7159  | https://doi.org/10.1038/s41598-020-63645-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Adipose-derived stem cells isolation. ASCs were isolated from adult Sprague–Dawley rats as previously 
reported15. Visceral fat was carefully dissected and minced using a sterile razor blade. Later, tissue was enzymati-
cally dissociated with 0.15% (w/v) collagenase type I (Invitrogen, UK) for 90 min at 37 °C under constant agitation. 
Collagenase was neutralized by the addition of α-Minimum Essential Medium Eagle (α-MEM, Sigma-Aldrich, 
Poole, UK) containing 10% (v/v) foetal bovine serum (FBS, LabTech, Uckfield, UK). Undissociated tissue was 
removed passing the solution through a 100μm filter and then centrifuged at 1200 rpm for 10 min. The stromal 
cell pellet was resuspended in α-MEM (Sigma-Aldrich, Poole, UK) containing 10% (v/v) FBS (LabTech, Uckfield, 
UK), 2mM L-glutamine (GE Healthcare UK, Little Chalfont, UK) and 1% (v/v) penicillin/streptomycin solution 
(Sigma-Aldrich, UK). Cultures were maintained at sub-confluent levels in a 37 °C incubator with 5% CO2.
ASCs differentiation towards Schwann-like phenotype. ASCs were differentiated into Schwann-like 
cells phenotype [SC-like adipose-derived stem cells (dASCs)] using a previously established protocol15,61.
Sub-confluent cultures of ASCs were incubated with α-MEM (Sigma-Aldrich, Poole, UK) containing 10% 
FBS (LabTech, Uckfield, UK) supplemented with 1 mM β-mercaptoethanol (Sigma-Aldrich, UK) for 24 h. 
Cells were washed twice with HBSS (Sigma-Aldrich, UK) and new medium supplemented with 35 ng/ml 
all-trans-retinoic acid (Sigma-Aldrich, UK) was added for 72 h. Afterwards cells were washed twice and trans-
ferred to α-MEM (Sigma-Aldrich, Poole, UK) containing 10% FBS (LabTech, Uckfield, UK) supplemented with 
5 ng/ml platelet-derived growth factor (PDGF; PeproTech Ltd., UK), 10 ng/ml basic fibroblast growth factor 
(bFGF; PeproTech Ltd., UK), 14 μM forskolin (Fsk; Sigma-Aldrich, UK) and 192 ng/ml glial growth factor-2 
(GGF-2, Acorda, Ardsley, NY, USA) (cell differentiation medium). Cells were incubated in cell differentiation 
medium for 2 weeks, passaged when sub-confluent, with fresh medium added approximately every 72 h.
Schwann cells cultures. SCs primary cultures were obtained from sciatic nerves dissected from 2-day-old 
Wistar pups, according to the protocol modified by Davis and Stroobant62. In brief, sciatic nerves were digested 
with trypsin/collagenase (Type I, Sigma-Aldrich, St. Louis, MA Louis, MA) and seeded into T25 flasks with fresh 
high glucose Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-Aldrich, Poole, UK) containing 10% foetal 
bovine serum (LabTech, Uckfield, UK). To selectively remove fibroblasts, cells were treated with 1 mM cytosine 
arabinoside (AraC, Sigma-Aldrich, UK) for 48 h and then with anti-Thy 1.1 (1:1000, Serotec, Bio-Radgroup, 
Hercules, CA) and rabbit complement (1:2 v/v) (Cedarlane, ON, Canada). SCs were then amplified in high glu-
cose Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma-Aldrich, Poole, UK), 10% FBS (LabTech, Uckfield, 
UK), 10 μM forskolin (Fsk; Sigma-Aldrich, UK) and 63 ng/ml glial growth factor-2 (GGF-2, Acorda, Ardsley, 
NY, USA).
SCs were incubated in 5% CO2 at 37 °C and maintained at sub-confluent levels onto Poly-D-Lysine (PDL, 
Sigma-Aldrich, UK)-coated 75 cm2 flasks.
cell treatments with cholinergic mimetics. Arecaidine Propargyl Ester hydrobromide (APE, 
Sigma-Aldrich, UK) is a preferring agonist of M2 receptor subtype. Its ability to selectively bind M2 muscarinic 
subtype has been previously demonstrated by pharmacological binding experiments and M2 knockdown in dif-
ferent cell culture models22,32,63,64. Muscarine (Sigma-Aldrich, UK) is a non-selective muscarinic receptor agonist. 
Both muscarinic ligands were used at the final concentration of 100μM21–23,32,33.
For pharmacological treatments, SCs and dASCs cultures were seeded in multi-6-well plates (Corning Life 
Sciences, USA) and incubated in their respective media. Once confluent, cells were rinsed and supplemented with 
fresh media containing 0.5% FBS (LabTech, Uckfield, UK) according to ELISA manufacturer’s protocols. After 
24 h or 48 h of treatment, cells were rinsed with ice-cold phosphate buffer solution (PBS) and scraped in RIPA 
lysis buffer (Sigma-Aldrich, UK) containing a cocktail of protease and phosphatase inhibitors (Thermo Scientific, 
Loughborough, UK). After 30 min of incubation on ice and a freeze-thaw cycle, lysates were centrifuged for 
20 min at 14000 rpm at 4 °C. Protein concentration was determined with the Bio-Rad detergent-compatible pro-
tein assay kit (Bio-Rad Laboratories, UK). The whole cell lysates were used for western blot analysis and ELISA 
of intracellular NGF as explained below. Cell media were collected and frozen until ELISA analyses. For qPCR 
analysis, cells were scraped with RNA cell protect reagent (Qiagen, Manchester, UK).
Real time pcR (qpcR). Cells were collected at the chosen time point (24 h) and stored in RNA cell protect 
agent (Qiagen, Manchester, UK). Total RNA was isolated from rat SCs and dASCs using RNeasy Plus Mini Kit 
(Qiagen, Manchester, UK), according to the manufacturer’s protocol. Each sample was reverse-transcribed using 
RT2 First Strand Kit (Qiagen, Manchester, UK), according to the manufacturer’s protocol. Real-time PCR was 
performed with RT2 SYBR Green qPCR Mastermix (Qiagen, Manchester, UK) using Corbett Rotor Gene 6000 
real-time cycler (Qiagen, UK). All reactions were carried out in triplicate and the following protocol used: hot 
start for 10 min at 95 °C, followed by 45 cycles of 15 sec at 95 °C, annealing for 30 sec at 55 °C and extension for 
30 sec at 72 °C. The sequences of the used primers are reported in Table 1. Data were normalized with 18 S house-
keeping gene and the ΔΔCt method was used to determine the fold changes in the gene expression, as compared 
to control.
immunocytochemistry. After fixation with 4% Paraformaldehyde (PFA) for 20 min at RT, cells were incu-
bated with 0.2% TritonX-100 for 30 min at RT. Then cells were washed twice with phosphate buffer Saline (PBS) 
and treated with block solution (PBS 0.1% TritonX-100 and 10% normal donkey serum (NDS)) for 1 h at RT. 
The next step was an incubation with primary antibody, rabbit anti-p75 NGF receptor antibody (Abcam, UK) 
at 4 °C overnight. The day after, cells were washed with PBS three times for 10 min and they were incubated 
with secondary antibody (Donkey anti-rabbit IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa 
Fluor 568, Life Technologies, UK) in 0.1% TritonX-100, 0.1% (w/v) BSA, 0.1% (w/v) Sodium Azide in PBS for 
1 h at RT. Afterwards, plates were washed 3 times with PBS and slides were mounted with Vectashield mounting 
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medium for fluorescence containing 4′-6′-diamidino-2-phenylindole for nuclear staining (H1200, Vector Lab, 
DBA, Milan, Italy). Images were taken using a fluorescence microscope (Olympus IX51, Southend-on-Sea, UK) 
and processed with ImageJ 64 imaging software (National Institutes of Health, NIH, 469 Bethesda, MD, USA).
protein extraction and Western blot. Cells were homogenized in ice-cold lysis buffer (20 mM Hepes pH 
7.9; 150 mM sodium chloride; 1% Nonidet P-40; 0.1 mM EDTA; 0.1 mM EGTA). Total protein content was evalu-
ated by DCTM Protein Assay (Biorad, Italy). Twenty micrograms of proteins were resolved in 8–12% SDS-PAGE, 
blotted onto nitrocellulose membrane and processed for Western blot according to what has been previously 
reported50. Used antibodies are detailed in Table 2. Densitometry was performed on scanned immunoblot images 
using ImageJ gel analysis tool (National Institutes of Health, NIH, 469 Bethesda, MD, USA). The optical density 
(OD) of each protein band was normalized against the OD of the β-actin band. The results from at least three 
independent experiments were averaged and the standard error of the mean (SEM) was calculated.
Enzyme-linked immunosorbent assay (ELISA). proNGF and mNGF content in cell lysates and condi-
tioned media was measured by specific ELISA, as previously described50. Briefly, capture antibody was the same 
for both the ELISA assays (Table 2) and was incubated overnight at room temperature (RT). Unbound antibody 
was removed by washing the plate once with washing buffer (0.5% (v/v) Tween-20 in PBS). After blocking 1 h 
at RT with 1% (w/v) BSA in PBS, the plate was rinsed with washing buffer and samples or standard curves were 
added to the wells and incubated for 2 h at RT. The microwells were then rinsed three times and incubated with 
specific detection antibodies dissolved in blocking buffer for 2 h, at RT. After three washes to remove unbound 
detection antibody, HRP-conjugated antibody, diluted in blocking buffer, was added and incubated for 1 h at 
RT. To visualize antibody reactivity, the chromogenic substrate 3’,3’,5’,5’-tetramethylbenzidine (TMB, cat. T8768, 
Sigma-Aldrich, UK) was used and colour development was stopped by adding 1 N HCl. The colorimetric reac-
tion was measured in absorbance mode at 450 nm by a Multiskan EX ELISA reader (Thermo Fisher Scientific 
Laboratory).
Zymography for matrix metalloproteinases (MMPs) detection and analysis of PAs activities. 
Gelatinolytic activity of conditioned media was assayed as previously described65. Aliquots of conditioned 
media were analysed on 7% sodium dodecyl sulfate polyacrylamide gel electrophoresis SDS-PAGE contain-
ing 0.1% gelatin under non-reducing conditions. Following electrophoresis, gels were washed twice in 2.5% 
TritonX-100 for 30 min at RT to remove SDS and then in water for 30 minutes. The gels were incubated at 37 °C 
overnight in substrate buffer, stained with 0.5% Coomassie Brilliant Blue R250 and distained in 30% methanol 
and 10% glacial acetic acid (vol⁄vol). To analyse PA activity, aliquots of conditioned media were separated by 
10% SDS-PAGE under non-reducing conditions66. After electrophoresis, gel was washed in 2.5% TritonX-100 
for 30 minutes at RT to remove SDS and then in water for 30 minutes. The TritonX-100 washed gel was placed on 
a casein-agar-plasminogen underlay, as previously described67. All the bands were plasminogen dependent. The 
gels were photographed and the densitometric analysis was performed using ImageJ software (National Institutes 
Primer Forward (5′-3′) Reverse (5′-3′)
NGF AAGGACGCAGCTTTCTATCC CTATCTGTGTACGGTTCTGCC
proNGF-A GTGTCCACCCATCTGCTAGG CACTGAGGTGAGCTTGGGTC
proNGF-B CCTGGAGCCGAAGGGGAG CACTGAGGTGAGCTTGGGTC
p75NTR CATCTCTGTGGACAGCCAGA CTCTACCTCCTCACGCTTGG
tPA AGCTAATCAGCTCAGCGCCAA CTCCCCGTTTCTTCCGTGTC
MMP2 CAGGGAATGAGTACTGGGTCTATT ACTCCAGTTAAAGGCAGCGTCTAC
18S GGATCCATTGGAGGGCAAGT ACGAGCTTTTTAACTGCAGCAA
Table 1. List of qPCR primers.
Primary antibody (catalog, manufacture) Application/Dilution Secondary antibody (catalog, manufacture, dilution)
rabbit anti-NGF M20 (sc-549, Santa Cruz) WB: 1:1000 HRP-linked anti-rabbit IgG7074, Cell Signaling 1:4000
mouse anti-β-actin (A5441, Sigma-Aldrich) WB: 1:10000 HRP-linked anti-mouse IgG 7076, Cell Signaling 1:5000
rabbit anti-proNGF
(EP1318Y, Abcam 68151) Detection ELISA: 1:5000
HRP-linked anti-rabbit IgG
7074, Cell Signaling 1:1000
goat anti-NGF
(AF-556-NA, R&D)
Capture
ELISA: 0.4 μg/ml
mouse anti-NGF 27/21 (52602, Millipore) Detection ELISA: 1:1000 HRP-linked anti-mouse IgG7076, Cell Signaling 1:1000
rabbit anti-p75NTR (Abcam, UK) ICC:1:100
Donkey anti-rabbit IgG (H + L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor 568
 Life Technologies 1:500
Table 2. List of antibodies.
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of Health, NIH, 469 Bethesda, MD, USA) to obtain semiquantitative estimation of protease activities. The values 
were normalized to protein content. Molecular weights were calculated from the position of pre-stained molecu-
lar weight markers subjected to electrophoresis in parallel lanes.
Data analysis. Data analyses were performed with GraphPad Prism (ver 7.0, GraphPad Software Inc, La Jolla, 
CA, USA). Data were presented as the mean ± standard error of the mean (SEM). Student’s t-test or one-way 
ANOVA analyses with Bonferroni’ or Tukey’s post-tests were used in Western Blotting and qPCR analyses. 
Statistical significance for the ELISA experiments were estimated by two-way ANOVA with Tukey’s post-tests. 
A value of p < 0.05 was considered statistically significant: p < 0.05(*), p < 0.01(**), and p < 0.001(***) 
p < 0.0001(****). The densitometric analysis of the RT-qPCR, Immunocytochemistry and Western blots were 
measured by ImageJ software (National Institutes of Health, NIH, 469 Bethesda, MD, USA).
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